MiR-214-3p regulates the viability, invasion, migration and EMT of TNBC cells by targeting ST6GAL1

  • Yun Tao
  • Zhijing Zhao
  • Junfeng Ma
  • Liying Dong
  • Ying Liang
  • Siqi Li
  • Ying Mao
  • Yan Li
  • Yi ZhangEmail author
Original Article


MiR-214-3p is concerned with the outcomes of various tumors, such as liver cancer, bladder cancer, etc. However, the role and target of miR-214-3p in triple negative breast cancer (TNBC) is not fully understood. This study took this as the entry point, with a view to find a potential target for TNBC. The expressions of miR-214-3p in TNBC tissues and cell lines were detected, and the effects of miR-214-3p inhibitor on the viability, migration, invasion and epithelial mesenchymal transition (EMT) of TNBC cells were further analyzed. The potential target of miR-214-3p were predicted and verified, as well as the effects of target silencing on the TNBC cells were also measured. MiR-214-3p was abnormally elevated in both TNBC tissues and cell lines, especially in MDA-MB-468 cells. Low-expression of miR-214-3p restrained the survival, migration, invasion and EMT of TNBC cells. ST6GAL1 was the target gene of miR-214-3p, and its expression level increased with the low-expression of miR-214-3p. ST6GAL1 expression was abnormally reduced in both TNBC tissues and cell lines. The silence of ST6GAL1 promoted the viability, migration, invasion and EMT of TNBC cells, which could be reversed by miR-214-3p inhibitor. The down-regulation of miR-214-3p could suppress the viability, migration, invasion and EMT of TNBC cells though targeting ST6GAL1, which might be a potential target for future treatment of TNBC. Up-regulation of miR-214-3p could promote the EMT of non-TNBC cells.


miR-214-3p Triple negative breast cancer ST6GAL1 Down-regulation Epithelial mesenchymal transition 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest.


  1. Antony P, Rose M, Heidenreich A, Knuchel R, Gaisa NT, Dahl E (2014) Epigenetic inactivation of ST6GAL1 in human bladder cancer. BMC Cancer 14:901. CrossRefPubMedPubMedCentralGoogle Scholar
  2. Araujo RF Jr, Lira GA, Vilaca JA, Guedes HG, Leitao MC, Lucena HF, Ramos CC (2015) Prognostic and diagnostic implications of MMP-2, MMP-9, and VEGF-alpha expressions in colorectal cancer. Pathol Res Pract 211:71–77. CrossRefPubMedGoogle Scholar
  3. Bill R, Christofori G (2015) The relevance of EMT in breast cancer metastasis: correlation or causality? FEBS Lett 589:1577–1587. CrossRefPubMedGoogle Scholar
  4. Cetin I, Topcul M (2014) Triple negative breast cancer. Asian Pac J Cancer Prevent 15:2427–2431CrossRefGoogle Scholar
  5. Dettori D et al (2018) Therapeutic silencing of miR-214 inhibits tumor progression in multiple mouse models molecular therapy. J Am Soc Gene Ther 26:2008–2018. CrossRefGoogle Scholar
  6. Feng M et al (2016) Lipocalin2 suppresses metastasis of colorectal cancer by attenuating NF-κB-dependent activation of snail and epithelial mesenchymal transition. Mol Cancer 15(1):77CrossRefGoogle Scholar
  7. Geyer FC, Pareja F, Weigelt B, Rakha E, Ellis IO, Schnitt SJ, Reis-Filho JS (2017) The spectrum of triple-negative breast disease: high- and low-grade lesions. Am J Pathol 187:2139–2151. CrossRefPubMedPubMedCentralGoogle Scholar
  8. Hu S, Zheng Q, Wu H, Wang C, Liu T, Zhou W (2017) miR-532 promoted gastric cancer migration and invasion by targeting NKD1. Life Sci 177:15–19. CrossRefPubMedGoogle Scholar
  9. Jhan JR, Andrechek ER (2017) Triple-negative breast cancer and the potential for targeted therapy. Pharmacogenomics 18:1595–1609. CrossRefPubMedPubMedCentralGoogle Scholar
  10. Jitariu AA, Cimpean AM, Ribatti D, Raica M (2017) Triple negative breast cancer: the kiss of death. Oncotarget 8:46652–46662. CrossRefPubMedPubMedCentralGoogle Scholar
  11. Kalniete D, Nakazawa-Miklasevica M, Strumfa I, Abolins A, Irmejs A, Gardovskis J, Miklasevics E (2015) High expression of miR-214 is associated with a worse disease-specific survival of the triple-negative breast cancer patients. Hered Cancer Clin Pract 13:7. CrossRefPubMedPubMedCentralGoogle Scholar
  12. Kotiyal S, Bhattacharya S (2014) Breast cancer stem cells, EMT and therapeutic targets. Biochem Biophys Res Commun 453:112–116. CrossRefPubMedGoogle Scholar
  13. Kumar P, Aggarwal R (2016) An overview of triple-negative breast cancer. Arch Gynecol Obstet 293:247–269. CrossRefPubMedGoogle Scholar
  14. Kumar S, Nag A, Mandal CC (2015) A comprehensive review on miR-200c a promising cancer biomarker with therapeutic potential. Curr Drug Targ 16:1381–1403CrossRefGoogle Scholar
  15. Li X et al (2017a) Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. Breast Cancer Res Treat 161:279–287. CrossRefPubMedGoogle Scholar
  16. Li Z, Takino T, Endo Y, Sato H (2017b) Activation of MMP-9 by membrane type-1 MMP/MMP-2 axis stimulates tumor metastasis. Cancer Sci 108:347–353. CrossRefPubMedPubMedCentralGoogle Scholar
  17. Liu Y et al (2017) MiRNAs predict the prognosis of patients with triple negative breast cancer: a meta-analysis. PloS ONE 12:e0170088. CrossRefPubMedPubMedCentralGoogle Scholar
  18. Lu X et al (2017) MiR-129-5p sensitizes the response of Her-2 positive breast cancer to trastuzumab by reducing Rps6. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol 44:2346–2356. CrossRefGoogle Scholar
  19. Mohr AM, Mott JL (2015) Overview of microRNA biology. Semin Liver Dis 35:003–011CrossRefGoogle Scholar
  20. Mouh FZ, Mzibri ME, Slaoui M, Amrani M (2016) Recent progress in triple negative breast cancer research. Asian Pac J Cancer Prevent 17:1595–1608CrossRefGoogle Scholar
  21. Nassar FJ, Nasr R, Talhouk R (2017) MicroRNAs as biomarkers for early breast cancer diagnosis, prognosis and therapy prediction. Pharmacol Ther 172:34–49. CrossRefPubMedGoogle Scholar
  22. Navratil J, Fabian P, Palacova M, Petrakova K, Vyzula R, Svoboda M (2015) [Triple negative breast cancer] klinicka onkologie: casopis. Ceske a Slov Onkol Spol 28:405–415Google Scholar
  23. Nie H, Nie D, Men L (2018) Role of miR-214 in modulating proliferation and invasion of human colon cancer SW620 cells. Oncol Lett 16:7175–7179. CrossRefPubMedPubMedCentralGoogle Scholar
  24. Noh MG et al (2017) Prognostic significance of E-cadherin and N-cadherin expression in gliomas. BMC Cancer 17:583. CrossRefPubMedPubMedCentralGoogle Scholar
  25. Orso F et al (2016) miR-214 and miR-148b targeting inhibits dissemination of melanoma and breast cancer. Cancer Res 76:5151–5162. CrossRefPubMedGoogle Scholar
  26. Palma G et al (2015) Triple negative breast cancer: looking for the missing link between biology and treatments. Oncotarget 6:26560–26574. CrossRefPubMedPubMedCentralGoogle Scholar
  27. Peng R, Men J, Ma R, Wang Q, Wang Y, Sun Y, Ren J (2017) miR-214 down-regulates ARL2 and suppresses growth and invasion of cervical cancer cells. Biochem Biophys Res Commun 484:623–630. CrossRefPubMedGoogle Scholar
  28. Petrovic N, Davidovic R, Bajic V, Obradovic M, Isenovic RE (2017) MicroRNA in breast cancer: the association with BRCA1/2. Cancer Biomarkers Sect A Dis Markers 19:119–128. CrossRefGoogle Scholar
  29. Puchinskaia MV (2015) Epithelial-mesenchymal transition in health and disease. Arkhiv Patologii 77:75CrossRefGoogle Scholar
  30. Rao X, Huang X, Zhou Z, Lin X (2013) An improvement of the 2Ë (-delta delta CT) method for quantitative real-time polymerase chain reaction data analysis. Biostat Bioinforma Biomath 3:71–85PubMedPubMedCentralGoogle Scholar
  31. Rupaimoole R, Slack FJ (2017) MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov 16:203–222. CrossRefPubMedPubMedCentralGoogle Scholar
  32. Schmadeka R, Harmon BE, Singh M (2014) Triple-negative breast carcinoma: current and emerging concepts. Am J Clin Pathol 141:462–477. CrossRefPubMedGoogle Scholar
  33. Simonson B, Das S (2015) MicroRNA therapeutics: the next magic bullet? Mini Rev Med Chem 15:467–474CrossRefGoogle Scholar
  34. Teoh SL, Das S (2017) The Role of MicroRNAs in diagnosis, prognosis, metastasis and resistant cases in breast cancer. Curr Pharm Des 23:1845–1859. CrossRefPubMedGoogle Scholar
  35. Wein L, Loi S (2017) Mechanisms of resistance of chemotherapy in early-stage triple negative breast cancer (TNBC). Breast (Edinburgh, Scotland) 34(1):27–30. CrossRefGoogle Scholar
  36. Wichert B, Milde-Langosch K, Galatenko V, Schmalfeldt B, Oliveira-Ferrer L (2018) Prognostic role of the sialyltransferase ST6GAL1 in ovarian cancer. Glycobiology 28:898–903. CrossRefPubMedGoogle Scholar
  37. Wong SHM, Fang CM, Chuah LH, Leong CO, Ngai SC (2018) E-cadherin: its dysregulation in carcinogenesis and clinical implications. Crit Rev Oncol/Hematol 121:11–22. CrossRefGoogle Scholar
  38. Xu Y et al (2018) LncRNA MT1JP Suppresses gastric cancer cell proliferation and migration through MT1JP/MiR-214-3p/RUNX3 axis. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol 46:2445–2459. CrossRefGoogle Scholar
  39. Yan S, Holderness BM, Li Z, Seidel GD, Gui J, Fisher JL, Ernstoff MS (2016) Epithelial-mesenchymal expression phenotype of primary melanoma and matched metastases and relationship with overall survival. Anticancer Res 36:6449–6456. CrossRefPubMedPubMedCentralGoogle Scholar
  40. Yang C, Tabatabaei SN, Ruan X, Hardy P (2017a) The dual regulatory role of MiR-181a in breast cancer. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol 44:843–856. CrossRefGoogle Scholar
  41. Yang SJ et al (2017b) The miR-30 family: versatile players in breast cancer. Tumour Biol J Int Soc Oncodevelopmental Biol Med 39:1010428317692204. CrossRefGoogle Scholar
  42. Yu H, Wang S, Zhu H, Rao D (2019) LncRNA MT1JP functions as a tumor suppressor via regulating miR-214-3p expression in bladder cancer. J Cell Physiol. CrossRefPubMedPubMedCentralGoogle Scholar
  43. Zhan M et al (2018) LncRNA HOXA11-AS promotes hepatocellular carcinoma progression by repressing miR-214-3p. J Cell Mol Med. CrossRefPubMedPubMedCentralGoogle Scholar
  44. Zhang Q, Zhang S (2017) miR-214 promotes radioresistance in human ovarian cancer cells by targeting PETN. Biosci Rep. CrossRefPubMedPubMedCentralGoogle Scholar
  45. Zhang S et al (2017) Differential expression of ST6GAL1 in the tumor progression of colorectal cancer. Biochem Biophys Res Commun 486:1090–1096. CrossRefPubMedGoogle Scholar
  46. Zhang Y et al (2019) Inhibition of miR214 attenuates the migration and invasion of triplenegative breast cancer cells. Mol Med Rep 19:4035–4042. CrossRefPubMedPubMedCentralGoogle Scholar
  47. Zhou J, Wang J, Zhang N, Zhang Y, Li Q (2015) Identification of biomechanical force as a novel inducer of epithelial-mesenchymal transition features in mechanical stretched skin. Am J Trans Res 7:2187Google Scholar

Copyright information

© Springer Nature B.V. 2019

Authors and Affiliations

  1. 1.Clinical Skill CenterKunming Medical UniversityKunmingChina
  2. 2.Department of Thyroid Breast SurgerySecond Affiliated Hospital of Kunming Medical UniversityKunmingChina

Personalised recommendations